

**S1 Table.** Response rates of recurrent uveal melanoma patients treated with surgery, TACE or RFA, radiotherapy, and systemic therapies (n=49)

Characteristic	Metastatectomy (n=7)	TACE, RFA (n=4)	RTx (n=3)	Only systemic Tx <sup>a)</sup> (n=27)	None (n=8)	p-value
<b>Disease control rate (DCR)</b>						
No. (%)	5 (71.4)	0	0	9 (33.3)		0.035
95% CI	24.98-84.25	0.00-54.59	0.00-54.59	22.64-56.05		
CR	1	0	0	0		
PR	2	0	0	0		
SD	2	0	0	9		
<b>OS2 (mo)</b>						
Median	134.73	8.00	9.20	15.67	7.605	0.05
95% CI	0.000-307.560	6.802-9.198	N/A	13.219-18.121	0.000-25.236	

OS2, overall survival 2 (defined as the time from recurrence of uveal melanoma to death from any cause); RTx, radiotherapy; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; Tx, treatment; 95% CI, 95% confidence interval; CR, complete response; PR, partial response; SD, stable disease. <sup>a)</sup>Includes chemotherapy (dacarbazine, platinum-based regimen, topotecan) and immunotherapy (interferon).